| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
ABT-702 (5-50 μM, 30 min) inhibited the release of TNF-α in amadori-glycosylated albumin (AGA)-induced microglia in a dose-dependent manner via A2AAR [2].
|
|---|---|
| ln Vivo |
ABT-702 (0.6–100 µmol/kg, intraperitoneal or appendiceal, single dose) has shown analgesic and anti-inflammatory effects in association with doses [1]. ABT-702 (1.5 mg/kg, intraperitoneal, three times a week for 8 weeks) improves the progression of diabetes by mediating signaling, oxidation and cell death [2]. ABT-702 (3 mg/kg, intraperitoneal, local 10 minutes before FDG injection) can significantly promote local reduction in the cerebellum, midbrain and medulla oblongata [3].
|
| Animal Protocol |
Animal/Disease Models: Male rats[1]
Doses: 0.6-100 µmol/kg Route of Administration: i.p., single dose Experimental Results: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia. Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema. Exhibited a non-opioid mechanism of action, as its effects were not reversed by the opioid antagonist naloxone. Showed less potential for developing antinociceptive tolerance compared to morphine. Animal/Disease Models: Male rats[1] Doses: 5-100 µmol/kg Route of Administration: p.o., single dose Experimental Results: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia. Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema. The antinociceptive and anti-inflammatory effects were blocked by selective adenosine receptor antagonists, confirming an adenosine-dependent mechanism. Exhibited a non-opioid mechanism of action. Showed less potential for developing antinociceptive tolerance compared to morphine. Had no significant effects on exploratory locomotor activity at lower analgesic doses. Reduced locomotor activity but did not impair motor coordination at higher doses. Had no significant effects on heart rate or mean arterial pressure at doses providing maximal anti-hyperalgesia. Animal/Disease Models: Male C57BL/6J (8 weeks) intraperitoneally injected with Streptozotocin (45 mg/kg, 5 consecutive days) to induce diabetes[2] Doses: 1.5 mg/kg Route of Administration: i.p., twice a week for 8 weeks Experimental Results: Showed no effects on final body weight and blood glucose levels in diabetic mice. Showed lower signs of inflammation (ICAM-1, TNF-α, and microglial activation marker Iba1) compared to control animals receiving the vehicle. Suppressed the upregulation of A₂A receptor and reduced ENT1 expression. Reduced oxidative and nitrosative stress in the retina. Blocked the diabetic effect on AK in diabetic mice as compared with vehicle-treated diabetic mice. Blocked cell death (decreased cleaved caspase-3 and TUNEL-positive cells) in diabetic mice but did not affect treated normal controls. Animal/Disease Models: Rats[3] Doses: 3 mg/kg Route of Administration: i.p., 10 minutes pre-FDG Experimental Results: Showed significant regional hypometabolism in the cerebellum, mesencephalic region, and medulla compared to the vehicle-treated rats. |
| References |
| Molecular Formula |
C22H19BRN6O
|
|---|---|
| Molecular Weight |
463.33
|
| CAS # |
214697-26-4
|
| Related CAS # |
ABT-702 dihydrochloride; ABT-702 hydrochloride
|
| Appearance |
Light yellow to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~53.96 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1583 mL | 10.7914 mL | 21.5829 mL | |
| 5 mM | 0.4317 mL | 2.1583 mL | 4.3166 mL | |
| 10 mM | 0.2158 mL | 1.0791 mL | 2.1583 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
